ClinicalTrials.gg
Enrolling by invitationNCT06620458FWHZ-DCBUpdated Oct 9, 2026

Influencing Factors and Outcomes of DCB Angioplasty

An observational study in Coronary Artery Disease, sponsored by Henan Institute of Cardiovascular Epidemiology. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Henan Institute of Cardiovascular Epidemiology · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Planned enrollment
30th of 218
5,000 · median 720
Started
2024
with 37 others
Observational
219 of 543
82 open now
Primary completion
2025-12
later than 62 of 209 live
Registered
404th of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 30th largest by planned enrollment of the 218 observational ones that give a count, is one of 38 that started in 2024, is one of 219 observational ones, reaches primary completion later than 62 of the 209 other live ones, and was the 404th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

171 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

This ambiprospective observational study evaluates the long-term safety and efficacy of Paclitaxel Drug-Coated Balloon (DCB) angioplasty in approximately 20,000 patients withcoronary artery lesions in large vessels. By combining retrospective historical data with a prospective registry involving biological specimen collection, the study aims to identify key predictors of outcomes, including intravascular imaging findings, hemodynamic parameters, and biological markers. Patients will be followed longitudinally for up to 10 years to assess the durability of the treatment and the incidence of major adverse cardiovascular events (MACE).

Read the detailed description

This is a large-scale, ambiprospective (bi-directional), observational cohort study designed to evaluate the efficacy and prognostic factors of Drug-Coated Balloon (DCB) angioplasty in patients withcoronary artery lesions in large vessels. The study aims to enroll approximately 20,000 patients, comprising both a retrospective cohort (historical data) and a prospective cohort (ongoing recruitment).

The primary objective is to investigate the impact of various determinants on clinical and angiographic outcomes. Specifically, the study will analyze differences in:

Baseline Characteristics: Demographics, comorbidities, and medication history. Lesion Features: Angiographic morphology, calcification, and lesion length. Intravascular Imaging: Quantitative and qualitative analysis using Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS).

Hemodynamic Parameters: Functional assessment indices such as Quantitative Flow Ratio (QFR) or Fractional Flow Reserve (FFR).

Procedural Approaches: Pre-dilation techniques, balloon sizing ratios, and inflation duration.

Biological Specimen Collection:

For the prospective cohort, biological samples (including peripheral venous blood) will be collected at baseline. These samples will be processed to isolate serum, plasma, and DNA/RNA for biobanking. The aim is to identify potential biomarkers (e.g., inflammatory markers, genetic polymorphisms, or metabolic profiles) associated with vascular remodeling, neointimal hyperplasia, and late lumen loss following DCB treatment.

Endpoints and Follow-up:

The study is designed to assess clinical and angiographic outcomes longitudinally. Follow-up assessments will be conducted at scheduled intervals (e.g., 1 year) and will extend to very long-term follow-up (up to 10 years). This extended observation period aims to evaluate the durability of the procedure and the long-term safety profile.

Clinical Endpoints: Major Adverse Cardiovascular Events (MACE), defined as a composite of cardiac death, target vessel myocardial infarction, and target lesion revascularization.

Angiographic Endpoints: Late Lumen Loss (LLL) and Binary Restenosis Rate assessed by Quantitative Coronary Angiography (QCA) at designated angiographic follow-up windows.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • DCB CHD IVUS OCT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This study targets adults aged 18 and over who have been diagnosed with coronary artery disease featuring native large vessel lesions and are scheduled to undergo paclitaxel drug-coated balloon angioplasty.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age:

    18 years and older.

  • Diagnosis:

Diagnosed with coronary artery disease with native large vessel lesions confirmed by coronary angiography.

  • Treatment Plan:

Scheduled to receive paclitaxel drug-coated balloon angioplasty.

  • :

Patients have been fully informed about the nature and purpose of the study, and have voluntarily agreed to participate, with signed informed consent.

  • Physiological Status:

Cardiac function classified as I-III.

Exclusion criteria

Exclusion Criteria:

  • Allergy History:

Known allergies to paclitaxel or any materials used in angioplasty (e.g., contrast agents).

  • Severe Complications:

Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg).

  • Other Medical Conditions:

Active bleeding or clotting disorders.

  • Other serious diseases with a of less than 1 year (e.g., advanced cancer).
  • Pregnancy or Nursing: Women who are currently pregnant or breastfeeding.
  • Participation in Other Studies: Currently participating in other clinical trials that might affect the results of this study.
  • Psychological or Behavioral Factors: History of psychiatric or behavioral disorders that could interfere with adherence to study protocols, or communication barriers that prevent understanding of study requirements.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
5,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Target Vessel Failure (TVF)

    Composite of cardiovascular death, target vessel myocardial infarction, or clinically driven target vessel revascularization, defined according to the Academic Research Consortium (ARC) criteria.

    Time frame: From the index procedure through up to 10 years of follow-up

Secondary outcomes

  1. Target Lesion Revascularization (TLR)

    Repeat percutaneous intervention or surgical bypass of the target lesion due to restenosis or other complications.

    Time frame: From the index procedure through up to 10 years of follow-up

  2. Target Vessel Revascularization (TVR)

    Any repeat revascularization of the target vessel

    Time frame: From the index procedure through up to 10 years of follow-up

  3. Major Adverse Cardiovascular Events (MACE)

    Composite of all-cause death, myocardial infarction, stroke, or any revascularization.

    Time frame: From the index procedure through up to 10 years of follow-up

  4. All-cause mortality

    Death from any cause.

    Time frame: From the index procedure through up to 10 years of follow-up

  5. Late lumen loss (LLL)

    Difference between post-procedural and follow-up minimal lumen diameter assessed by quantitative coronary angiography.

    Time frame: At the first available follow-up coronary angiography, up to 10 years

  6. Binary restenosis

    Diameter stenosis ≥50% at follow-up angiography.

    Time frame: At the first available follow-up coronary angiography, up to 10 years

  7. Quantitative Flow Ratio (QFR)

    Functional assessment of coronary physiology derived from angiography.

    Time frame: Immediately after the index DCB procedure and at the first available follow-up coronary angiography, up to 10 years

  8. Bleeding Events

    Classified by BARC (Type 1-5) at 12 months.

    Time frame: 12 months after the index procedure

  9. cardiovascular death

    Death due to cardiovascular causes, including death caused by acute myocardial infarction, sudden cardiac death (including unwitnessed death), heart failure, stroke, cardiovascular procedures, or cardiovascular hemorrhage, according to the Drug-Coated Balloon Academic Research Consortium (DCB-ARC) criteria.

    Time frame: Up to 5 years after the index DCB procedure

  10. Myocardial Infarction (MI)

    Occurrence of myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction. Both target-vessel and non-target-vessel myocardial infarctions will be recorded.

    Time frame: From the index procedure through up to 10 years of follow-up.

  11. Target Vessel Myocardial Infarction (TV-MI)

    Myocardial infarction attributable to the target vessel. This includes myocardial infarction related to the DCB-treated target lesion and myocardial infarction arising from a non-target lesion within the same target vessel.

    Time frame: From the index procedure through up to 10 years of follow-up.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Dec 2025, 14 months.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 14 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2024
First posted
Oct 1, 2024
StartActual
Oct 1, 2024
Primary completionActual
Dec 1, 2025
CompletionEst.
Dec 1, 2030
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06620458
Lead sponsor
Henan Institute of Cardiovascular Epidemiology
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Oct 1, 2024
Primary completion
Dec 1, 2025
Completion
Dec 1, 2030 (estimated)
Last update
Oct 9, 2026

Study contacts

Muwei Li, Ph.D
study chair · Fuwai central China cardiovascular hospotial

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion